Eli Lilly and Company, along with partner institutions in the US and United Kingdom, describe how short-term pharmacologic intervention does not appear to have lasting effects for most tirzepatide patients. People with obesity who lost weight on tirzepatide often regained at least 25% of that loss within a year of stopping treatment, along with reversals in improvements in waist circumference, blood pressure, lipids, and glycemic measures.
This article was originally published on MedicalXpress.com
